NDAORALCAPSULE
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
CESAMET (nabilone) by Bausch + Lomb. Approved for cannabinoid [epc]. First approved in 1985.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CESAMET (nabilone) is a synthetic cannabinoid oral capsule approved in 1985 for chemotherapy-induced nausea and vomiting. It is a Schedule II controlled substance that acts as a cannabinoid receptor agonist to reduce emetic symptoms in cancer patients undergoing chemotherapy.
LOE Approaching
Product lifecycle transitioning toward loss of exclusivity signals potential organizational restructuring and reduced commercial investment in brand support.
Mechanism of Action
Pharmacologic Class:
Cannabinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis
Started Jun 2007
50 enrolled
Neuropathic PainMultiple Sclerosis
A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting
Started Aug 2006
16 enrolled
Nausea and Vomiting
Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients
Started Dec 2005
16 enrolled
PainInsomnia
Career Relevance
With zero linked job openings and a product approaching LOE, this represents a low-growth career opportunity within a mature, legacy brand under Bausch + Lomb ownership. Professionals joining this team should expect defensive positioning and potential organizational contraction rather than expansion.
Worked on CESAMET at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.